Pulmatrix Inc PULM

NAS: PULM | ISIN: US74584P2020   19:39
1,970 USD (+3,14%)
(+3,14%)   19:39
Grafiek Pulmatrix Inc Grafiek Pulmatrix Inc

Pulmatrix Inc in het nieuws

15 mei 2024 · Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) · Persbericht

15 mei 2024 · Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) · Persbericht

10 mei 2024 · Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

28 maart 2024 · Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update · Persbericht

8 januari 2024 · Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives · Persbericht

9 november 2023 · Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update · Persbericht

19 september 2023 · Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine · Persbericht

23 augustus 2023 · Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole · Persbericht

10 augustus 2023 · Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update · Persbericht

11 juli 2023 · Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine · Persbericht

Profiel Pulmatrix Inc

Biotechnologie
Fabricage van farmaceutische preparaten
Gezondheidstechnologie
Productie

Website: www.pulmatrix.com

Hoofdzetel: Lexington, Massachusetts vlag Verenigde Staten

CEO: Teofilo Raad

Werknemers: 35

Aandelen Pulmatrix Inc

Beurswaarde: 6,98 miljoen USD

Effecten: 3,65 miljoen

Beta: 0,01

Mijn selecties